High cholesterol absorption is associated with increased cardiovascular risk in haemodialysis patients: insights from the AURORA study.

Date publication

mai 2022

Journal

European journal of preventive cardiology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick

Tous les auteurs :
Silbernagel G, Duarte K, Sadiku S, Fauler G, März W, Schmieder RE, Jardine AG, Massy ZA, Girerd N, Fellström B, Rossignol P, Scharnagl H, Zannad F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35512252

Résumé

Statin treatment did not reduce the risk of cardiovascular events in haemodialysis patients in the 4D and AURORA trials. Post hoc analyses in the 4D study suggested that high cholesterol absorption was associated with increased cardiovascular risk and that atorvastatin would reduce cardiovascular risk in haemodialysis patients with low cholesterol absorption but not in those with high cholesterol absorption.

Mots clés

Cardiovascular risk, Cholestanol, Cholesterol, Cholesterol absorption, Hemodialysis, Randomized controlled trial, Rosuvastatin

Référence

Eur J Prev Cardiol. 2022 May 4;: